Back to Top

Information For Authors

Aims & Scope

Cannabis and Cannabinoid Research is the only peer-reviewed journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids. The Journal publishes a broad range of human and animal studies including basic and translational research; clinical studies; behavioral, social, and epidemiological issues; and ethical, legal, and regulatory controversies.

Cannabis and Cannabinoid Research is the premier source for authoritative cannabis and cannabinoid research, discussion, and debate. All articles in Cannabis and Cannabinoid Research are rapidly reviewed and published online within 4 weeks of acceptance. 

Submitting to the Journal

Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, except in the form of an abstract. By submitting a manuscript to the Journal, the author(s) agree(s) to each of these conditions. Prior abstract publications should be described in the form of a footnote to the title.

Manuscripts to be considered for publication must be submitted online via

Please note that all manuscripts submitted after March 1, 2020 will be subject to a nominal fee to publish color figures, including online.  For more information regarding color publication, contact

All submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.

Keywords (Areas of Expertise)

To facilitate the peer review process, select 4-6 keywords from the drop-down list of pre-selected terms when submitting your manuscript.   These keywords will assist in the selection of skilled reviewers in the field for the purposes of peer review.

Manuscript keywords (search terms): On the title page of the manuscript, include a minimum of three (3), maximum of six (6), search terms that will aid in the discoverability of the article in indexing services and search engines.  These terms may or may not be different from the terms you selected for the peer review process and areas of expertise.  You will be asked to retype these search terms in the submission form when uploading your manuscript.  These keywords will be included in the published article.  If the search terms entered do not match the manuscript, the manuscript will serve as the default.

The Journal will publish basic science and translational research in the form of the following article types:

  • Original Research:  Full-length descriptions of original research on cannabis, cannabinoids, and the endocannabinoid system. The investigation may focus on basic science or clinical outcomes.  Word limit: 3,000 words excluding references, figures, and tables with a structured abstract of 350 words or less.
  • Comprehensive Reviews:  Appraisals of research and clinical trials in fields of current interest. While these are subject to the same review process as other papers, authors are encouraged to speculate about future promise of new procedures and techniques. Unsolicited reviews are welcome.  Word limit:  5,000 words excluding references, figures, and tables with a structured abstract of 350 words or less.
  • Mini-reviews:  Brief summaries of developments in fast-moving areas of research, and must be must be based on published articles. Mini-reviews must not exceed 2,500 words excluding references, figures, and tables and should contain a structured abstract of 300 words or less.
  • Rapid Communications:  Intended for the accelerated publication of cutting-edge, groundbreaking biomedical findings. Word limit: 1,500 words excluding references with no more than two figures or tables.  A structured abstract of 200 words or less is required.
  • Technical Reports: Briefly and succinctly describe improvements or helpful modifications in current procedures.  Word limit:  2,000 words excluding references, figures, and tables.  Abstract not required.
  • Perspectives are representative of an opinion about an area of the field or a direction of research. The length for either should not exceed 2,000 words and should be accompanied by a structured abstract of 250 words or less.
  • Literature Reviews:  Reviews of a topical area of research relevant to  the journal, discussing the work of multiple research groups.  Word limit, 1,500 words excluding references, figures, and tables, with a structured abstract of no more than 250 words. 
  • Meeting Reports:  Accounts of a representative sample of talks or poster presentations at a recent conference or symposium.  1,500 word limit.  Abstract not required.
  • Letters to the Editor:  A forum for presentation of preliminary clinical results and advances in technology,  In addition, letters extending, contesting, challenging, or disputing claims advanced in previous publications are encouraged and will be submitted to the original authors for comment.  Word limit:  750 words with no more than four references and one figure or table.  Abstract not required.


Copyright and Licensing

Upon acceptance of a paper, each author listed on a manuscript will receive an email containing a unique URL specific to their authorship.  The corresponding author is responsible for communicating with co-authors to ensure they have completed their individual copyright forms.  Authors not permitted to release copyright must contact the Journal in writing explaining the reason(s) for not releasing the copyright.  Failure by any author(s) listed on a paper to submit this form WILL result in a delay in publication.  An accepted paper will not be released to production without the receipt of all copyright forms.


CCBY licensing is available upon request.  Please contact for more information.

Archiving and Preservation
Mary Ann Liebert, Inc., deposits and archives all publications in Portico for long-term digital preservation.   Cannabis and Cannabinoid Research is fully NIH-, HHMI-, and Wellcome Trust-compliant. 


Corresponding Authorship

It is the Journal’s policy that a manuscript has only ONE corresponding author listed on a paper.  This designation should be determined at the time of submission.  Changes to corresponding authorship are not permitted after acceptance or in page proofs.

Peer Review Process and Policy
Manuscripts are typically reviewed by two or more peer reviewers in the field of study and are expected to meet the standards of academic and scientific excellence.  The initial review process usually takes between 4-10 weeks; revisions require additional time.  Each reviewer is asked to provide constructive comments to aid authors in improving their work for publication, either in Cannabis and Cannabinoid Research or elsewhere if it is rejected.  The final decision to accept or reject a paper is made by the Editor-in-Chief after the review process is complete.

Authors are encouraged to supply the names and email addresses of 3–4 individuals who are considered qualified to review the submitted material, as well as the names of individuals whom the authors would prefer not be included in the review process along with the reason for this request. However, reviewers are ultimately selected at the discretion of the Editor.

Manuscripts submitted to Cannabis and Cannabinoid Research will not be rejected solely on the basis of errors in sentence construction, syntax, and grammar. Cannabis and Cannabinoid Research strives to communicate meritorious research from all countries, and reviews will not be compromised due to deficiencies in presentations. However, manuscripts which require substantial editing may, at the editors’ discretion, be un-submitted and referred to an editorial service for a fee (subsidized by the authors). Please contact for more details.  It is important to note that use of this service does not guarantee acceptance.

Ethical Considerations in the Conduct and Reporting of Research: Protection of Human Subjects and Animals in Research

When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed.


Human Subjects

Patient Consent/Release

If applicable, it is incumbent upon the author(s) to obtain patient release statements of permission to reproduce any identifiable images of patients. The Journal does not provide a generic patient release form.

Any identifying information should not be published in descriptions or photographs unless the information is essential for scientific purposes and the patient (or parent/guardian) gives written informed consent for publication. Informed consent for this purpose requires that an identifiable patient be shown the manuscript to be submitted. Authors should disclose to these patients whether any potential identifiable material might be available via the Internet as well as in print after publication.]]  Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are de-identified, the manuscript should contain assurances/statements that such changes do not distort scientific meaning.

 In keeping with patients' rights of privacy, the Journal does not require the submission of patient consent forms, but instead requires the author(s) to retain and archive all patient consent documentation. Upon submission of a manuscript for review, the authors must make a statement in a cover letter to the Editor/Journal which attests they have received and archived written patient consent.

Ethics of Experimentation

All articles involving the use of human fetuses, fetal tissue, embryos, and embryonic cells must adhere to the US Public Law 103–41, effective December 13, 2001. (

Ethical Treatment of Animals

All peer-reviewed submissions containing animal experiments must comply with local and national regulatory principles, and contain a statement in the Materials and Methods section stating whether their national and institutional guidelines for the care and use of laboratory animals were followed.

Preparation of Manuscripts

Manuscripts should be should be prepared in Microsoft Word and double-spaced.

Please follow these guidelines for submitting figures:  

    • Do NOT embed art files into a Word or PDF document
    • Name figure files using only alphanumeric characters.  Do not use symbols, underscores, spaces, dots, or dashes.
    • File names must be in English
    • File names should be formatted with first author’s last name and the figure number. (Ex:  SmithFig1)
    • Line illustrations should be submitted at 900 dpi
    • Halftones and color should be submitted at a minimum of 300 dpi
    •  Save as either TIFF or EPS files. 
    • Black and White art must be submitted as grayscale – not RGB
    • Excel files cannot be uploaded. It is best to avoid submitted PowerPoint files.  For directions on how to convert a Power Point slide to an acceptable format go to
    • Supplemental Information (if applicable); NOTE: Supplemental Information will not be copyedited or typeset; it will be posted online as supplied.)

Please name your artwork files with the first author’s last name, and figure/table number.
Ex: SmithFig1; SmithTable2; etc.

Additional Information: Art Files
Converting Word or Excel files: Perhaps the best and easiest way to convert Word or Excel files into a format which is suitable for print is to scan them using the below guidelines:

• All files should be scanned at 100% size

• 300 dpi

• Save file as: .tif or .eps

Sequencing Sections
The title page should contain: A) the complete title of the paper; B) the full name, complete affiliation information (including country if outside the US) for each author; C) a brief running title consisting of no more than 45 characters (including spaces); D) the corresponding author’s complete contact information including address and valid e-mail address.

Footnotes and abbreviations: List information such as prior conference presentation of the submitted material and a list of non-standard abbreviations (standard abbreviations need not be listed).

Abstract:  Structured.  See manuscript types for word limits.

Introduction: Describe the background leading to the study and clearly state the purpose of the study or its major contribution.

Materials and Methods: Provide sufficient information to permit both reproduction of the results by other investigators and appropriate critical evaluation of the procedures used.

Discussion: The results and discussion sections of short papers may be combined for more effective presentation.



Use this section of the paper to recognize or thank individuals who have participated in a portion of the work associated with the paper, but who do not meet the criteria for authorship.**  Some examples of this type of recognition include, but not limited to the following: supervisory staff, administrative support, acquisition of funding or equipment, technical and/or language editing, proofreaders, or individuals who supplied materials or collected data.

**For further information on authorship criteria, visit the International Committee of Medical Journal Editors’ website at:

Author/Conflict of Interest Disclosure Statement (required): 

Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at for further guidance.  If no conflicts exist, the authors must clearly state “No competing financial interests exist."

Funding Information (required):

Include the full name (do not abbreviate) of any funding agency(ies)/institution(s) and list all associated grant numbers.  Ensure the accuracy of grant numbers and be sure to include all grants.  If the work did not receive funding, this must be clearly stated.


Should be cited in the text and listed numerically at the end of the paper in the order of citation, as detailed in instructions below.

Figure legends:

These must be double-spaced in a separate file.

Tables: Number these consecutively throughout the text. Tables should be prepared in a separate file, and should not be included as part of the main text document.


References may be made to published work and papers in press. Reference citations are not permitted in the abstract of a paper. Authors are responsible for the accuracy of all literature citations. Work in progress, in preparation, unpublished work, and personal communications should be cited as footnotes to the text. References should be listed numerically in the text in the order of appearance as superscripted consecutive numbers, e.g., 1,2. Where there are more than two references, the in-text citation should appear as hyphenated numbers, e.g., 1–3. The reference section should be typed double-spaced in numerical order of citation, with the first three authors listed, followed by et al. Abbreviations of journals titles should conform to those used in Medline. The following formats must be used:

Journal Articles
Hartman RL, Brown TL, Milavetz G, et al. Controlled cannabis vaporizer administration: blood and plasma cannabinoids with and without alcohol. Clin Chem. 2015;61:850-869.


Cervantes J. The Cannabis Encyclopedia: the definitive guide to cultivation & consumption of medical marijuana.  Van Patten Publishing: Vancouver, WA, 2015.


Unpublished Material

When a reference is unpublished data, a manuscript in preparation, or a manuscript submitted but not in press, it should be included in parentheses in the body of the text, and not cited in the reference list. Personal communications should also be listed parenthetically in text, and should contain the first initial and last name of the contact, as well as the month and year of the communication. Published manuscripts, and those that have been accepted and are pending publication, should be cited in the reference list.


Page Proofs

Page proofs will be sent to the (one) corresponding author as designated when the manuscript was uploaded to Manuscript Central.  It is the corresponding author’s responsibility to share the page proofs with co-authors and to coordinate all authors’ corrections into one proof.  The Publisher will not accept corrections from multiple authors.


Changes in Authorship after acceptance are not permitted.



When reproducing copyrighted material such as figures or tables, the author must obtain permission from the original publisher and submit it concurrently with the manuscript.  Written permission must be obtained from the publisher of the journal or book concerned. The publication from which the figure or table is taken must be listed in the reference list. Finally, a footnote to a reprinted table or the legend of a reprinted figure should read, “Reprinted by permission from Jones et al.” and list the appropriate reference. All permissions must be supplied at the time of submission.

Fees for Color Images

The Journal will publish color photographs, but the author will be charged for the cost of color printing. For further details, contact the Publisher at



Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs. Reprints ordered after the issue is printed will be charged at a substantially higher rate.


Cannabis and Cannabinoid Research is published and owned by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215. Telephone: (914) 740–2100; Fax: (914) 740–2101; Website:; Email:


Liebert Open Access

Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) option

Explore Liebert Open Access

Does your research funder have an open access mandate or would you like to expand the dissemination of your research?

The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.

The benefits of Liebert Open Access include:

  • High visibility; open access articles are freely available online upon publication
  • You retain copyright with the open access license allowing broad dissemination of your research
  • You can freely share your article in repositories and research networks without restrictions
  • Easy compliance with open access mandates
  • Rigorous editorial and peer-review
  • Targeted email announcement featuring a direct link to article

Identification and Marketing

Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.

Copyright and Licensing

If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

At this time we allow authors to choose between the CC-BY or CC-BY-NonCommercial license. A limited number of journals offer NonCommercial licenses exclusively.

Ordering Open Access

Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email

Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form.  You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.

Publishing biomedical or biotechnology research?

Biomedical researchers should consider publishing in BioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.

 *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.


Browse journals in the Liebert Open Access portfolio:

Cannabis and Cannabinoid Research is fully compliant with NIH-, HHMI-, Wellcome Trust-, RCUK-, and major funder open access policies.

Publishing in Subscription Journals

By signing the copyright transfer statement, authors still retain a set of rights that allow for self-archiving.

Authors may archive their preprint manuscripts (version prior to peer review) at any time without restrictions. Authors may archive their postprint manuscripts (accepted version after peer review) in institutional repositories, preprint servers, and research networks after a 12 month embargo. The 12 month embargo period begins when the article is published online. Postprints must not be used for commercial purposes and acknowledgement must be given to the final publication, and publisher, by inserting the DOI number of the article in the following sentence: “Final publication is available from Mary Ann Liebert, Inc., publishers[insert DOI]”. Authors may archive on their personal website without an embargo provided their manuscript is updated with an acknowledgement to the publisher copyright and final published version.

The final published article (version of record) can never be archived in a repository, preprint server, or research network.


Publishing Open Access

Authors that wish to easily comply with funder or institutional open access mandates should consider publishing open access. Liebert Open Access option allows authors to make their research freely available online without restrictions. Additionally, Liebert Open Access option allows authors to retain copyright, archive and share the final published version of their article without restrictions. To publish open access please email or visit Liebert Open Access for more information.

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Upcoming Events

Mar 29 - Mar 31, 2021